Applicant Investment
ProTA Therapeutics Pty Ltd (OneVentures Healthcare Fund III) OneVentures Healthcare Fund III has committed $10 million to ProTA Therapeutics to advance the development of a promising new treatments of food allergies in children and adults. 
Rex Bionics (BioScience Managers Translation Fund 1) BioScience Managers Translation Fund 1 has invested $12.2 million to Rex Bionics to develop a hands-free robotic device to help people with severe disability to walk, exercise and rehabilitate.
Saluda Medical (BioScience Managers Translation Fund 1) BioScience Managers Translation Fund 1 has invested $3.3 million to Saluda Medical for neuromodulation technologies for people suffering from chronic back pain and other debilitating conditions.
SummatiX Pty Ltd (BioScience Managers Translation Fund 1) BioScience Managers Translation Fund 1 has committed $12.03 million to SummatiX Pty Ltd for data aggregation and commercialisation services for makers of 'smart' medical devices.
Global Kinetics Corporation (MRCF-BTF Fund and BioScience Managers Translation Fund 1) Brandon Capital Partners' MRCF BTF Fund and BioScience Managers Translation Fund 1 has invested $27.4 million into Global Kinetics Corporation to accelerate the development and commercialisation of a wrist-worn device that measures symptoms and provides clinical reports to assist with planning routine care for Parkinson's patients.
BiVACOR Pty Ltd (OneVentures Healthcare Fund III) OneVentures Healthcare Fund III has invested $19 million to BiVACOR, a company that is developing a rotary total artificial heart device that could provide a life-saving solution for individuals requiring a new heart.
Avita Medical Ltd (BioScience Managers Translation Fund 1) BioScience Managers Translation Fund 1 has invested $6.5 million to Avita Medical Ltd for improved skin regeneration through a unique process using the patient's own skin.
Aravax Pty Ltd (MRCF-BTF Fund) Brandon Capital Partners' MRCF BTF Fund has invested $7.73 million into Aravax Pty Ltd for a novel form of peptide immunotherapy to treat peanut allergy.
GI Therapies Pty Ltd (MRCF-BTF Fund) Brandon Capital Partners' MRCF BTF Fund has invested $1.8 million to GI Therapies Pty Ltd to develop a device to treat a range of gastrointestinal motility disorders.
Certa Therapeutics Pty Ltd (MRCF-BTF Fund) Brandon Capital Partners' MRCF-BTF Fund has committed $22 million to Certa Therapeutics to progress the clinical development of a drug to treat kidney disease.
Paragen Bio Pty Ltd (OneVentures Healthcare Fund III) OneVentures Healthcare Fund III has committed up to $2 million to Paragen Bio Pty Ltd, a company that is developing treatments to target autoimmune diseases using the beneficial proteins found in parasitic hookworms.
Respirion Pharmaceuticals Pty Ltd (MRCF-BTF Fund) Brandon Capital Partners’ MRCF-BTF Fund has committed $20 million to Respirion Pharmaceuticals Pty Ltd to fund clinical trials and product development in a new therapy for the treatment of Cystic Fibrosis.
Madorra Pty Ltd (OneVentures Healthcare Fund III) OneVentures Healthcare Fund III has invested $4.7 million to Madorra Pty Ltd. The company is working towards changing the paradigm for treating vaginal dryness for post-menopausal women and breast cancer survivors, by providing a medical device solution to a problem that has previously only been served by pharmaceuticals.
Blade Therapeutics Pty Ltd (OneVentures Healthcare Fund III) OneVentures Healthcare Fund III has invested $27.5 million to Blade Therapeutics Pty Ltd to assist in the development of a drug to treat fibrosis. Fibrosis is a disease with a high morbidity rate which affects many organs, for which there is no effective treatment. It particularly affects the lungs, kidneys and liver.
Denteric Pty Ltd (MRCF-BTF Fund) MRCF-BTF Fund has committed $9.23 million into Denteric Pty Ltd to assist in the development of a vaccine that will prevent severe gum disease, which is highly prevalent around the world and causes significant issues such as bone erosion and tooth loss. Severe gum disease has also been linked to many other health problems such as diabetes, heart disease, stroke and Alzheimers Disease.
George Medicines Pty Ltd (MRCF-BTF Fund) Brandon Capital Partners' MRCF-BTF Fund has committed $20 million to George Medicines Pty Ltd to develop novel drug formulations to treat major cardio diseases such as heart attack and stroke. Over 2 billion people globally suffer from cardio-based diseases and it is a common cause of premature death.
Kira Biotech (OneVentures Healthcare Fund III) OneVentures Healthcare Fund III has committed $9.5 million to Kira Biotech. Kira Biotech is researching treatments for autoimmune disease, a condition where the immune system attacks healthy cells or the body’s organs. Kira Biotech’s research directs components of the body’s normal immune response to the impaired cells of a person suffering from an autoimmune disease, allowing the immune system to work properly.
Closed Loop Medical (BioScience Managers Translation Fund 1) BioScience Managers Translation Fund 1 has committed $10 million to medical device company Closed Loop Medical. Closed Loop Medical’s technology aims to improve treatments for conditions of the body’s nervous system. The technology being developed will record and measure a person’s unique response to stimulation and provide a tailored outcome for the patient. The technology has the potential to be applied to disorders including Parkinson’s disease, epilepsy and bladder dysfunction.
Polyactiva Pty Ltd (MRCF BTF Fund) Brandon Capital Partners’ MRCF BTF Fund has invested $8.2 million in Polyactiva. Polyactiva’s novel polymer technology delivers medication to the eyes. Its lead product will be used for treating glaucoma, the leading cause of blindness affecting 70 million people globally. Polyactiva’s novel delivery technology will provide six months of therapy from a single treatment, overcoming many of the challenges of delivering medication with eye drops.
Adherium (BioScience Managers Translation Fund 1) BioScience Managers Translation Fund 1 has also invested $10 million to Adherium. Adherium is developing a digital medication monitoring system for people with respiratory diseases. The monitoring system will initially help people with conditions like asthma by tracking their drug usage and issuing reminders to ensure they take their medication.
Axelia Oncology (MRCF BTF Fund) Brandon Capital Partners’ MRCF BTF Fund has committed $5.6 million from the fund to Axelia Oncology. Axelia Oncology is a biotechnology company that is developing a novel innate immodulator with a distinct mechanism of action for the treatment of solid tumours.
Ena Respiratory (MRCF BTF Fund) Brandon Capital Partners’ MRCF BTF Fund has committed $13.8 million from the fund to Ena Respiratory to test a nasal spray treatment that protects at the primary site of most respiratory virus infections, including SARS- CoV-2 (the strain of coronavirus that causes COVID-19) and influenza. It is based on research that has come out of the Department of Immunology / Peter Doherty Institute for infection and Immunity at the University of Melbourne.
Cynata Therapeutics Ltd (Bioscience Managers Translation Fund 1) BioScience Mangers Translation Fund 1 has committed $10 million to Cynata Therapeutics Ltd. Cynata Therapeutics Ltd is an Australian stem cell and regenerative medicine company developing a therapeutic cell platform technology, Cymerus. The Cymerus platform stem cell technology is based on important and versatile stem cells known as mesenchymoangioblasts (MCAs) which give rise to mesenchymal stem cells (MSCs). MSCs are at the forefront of a new generation of treatments being investigated for devastating diseases including Osteoarthritis, diabetic foot ulcers, respiratory disease, Crohn’s disease and heart disease.
Acrux Ltd (Bioscience Managers Translation Fund 1) BioScience Mangers Translation Fund 1 has committed $5 million to Acrux Ltd. Acrux Ltd has a successful track record in developing and commercialising new products to increase the range of everyday medicines that can be applied for a local effect or absorbed through the skin. These gels, creams and ointments provide a viable alternative to needle injections or oral medications that may need to be taken several times a day and may have an unpleasant taste.
Axial Biotherapeutics Pty Ltd (OneVentures Healthcare Fund III) OneVentures Healthcare Fund III has committed $10.3 million to Axial Therapeutics Pty Ltd. Axial Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics for central nervous system disorders. The company is leveraging its expertise in the gut-brain axis and its unique drug development platform to advance novel therapies that have the potential to transform the treatment paradigm in neurodegenerative (conditions which affect cells in the brain called neurons) diseases. Drugs in development may also have applications in the treatment of certain cancers.
 OccuRx (MRCF – BTF Fund)  Brandon Capital Partners’ MRCF-BTF Fund has invested $8 million in OccuRx to develop novel medicines for the treatment of diabetic complications, including diabetic kidney disease and diabetic eye disease.
 OncoRes (MRCF – BTF Fund)  Brandon Capital Partners’ MRCF-BTF Fund has invest $4.1 million in OncoRes to develop a tool to translate touch into microscale images. This will assist surgeons in accurately identifying and removing cancerous tumours.